



ORIGINAL ARTICLE

In vitro anti-tuberculosis activity of azole drugs against *Mycobacterium tuberculosis* clinical isolates



Belén R. Imperiale^a, Ángel A. Cataldi^{b,*}, Nora S. Morcillo^a

^a Reference Laboratory of Tuberculosis Control Program of Buenos Aires Province, Dr. Cetrangolo Hospital, Italia 1750, Florida 1602, Buenos Aires Province, Argentina

^b Biotechnology Institute, National Institute of Agricultural Technology (INTA), Los Reseros y Nicolás Repetto s/n, 1686 Hurlingham, Buenos Aires Province, Argentina

Received 13 July 2016; accepted 23 February 2017

Available online 15 September 2017

KEYWORDS

Drug resistance;
Imidazole;
Latent tuberculosis;
Nitroimidazole

Abstract

Background: Latent tuberculosis has been associated with the persistence of dormant *Mycobacterium tuberculosis* in the organism of infected individuals, who are reservoirs of the bacilli and the source for spreading the disease in the community. New active anti-TB drugs exerting their metabolic action at different stages and on latent/dormant bacilli are urgently required to avoid endogenous reactivations and to be part of treatments of multi- and extensively-drug resistant tuberculosis (M/XDR-TB). It was previously reported that azole drugs are active against *M. tuberculosis*. For that reason, the aims of this study were to determine the *in vitro* activity of azole drugs, imidazole (clotrimazole, CLO and econazole, ECO) and nitroimidazole (metronidazole, MZ and ipronidazole, IPZ), against a collection of MDR *M. tuberculosis* clinical isolates; and to analyze their potential use in both the LTB and the active forms of M/XDR-TB treatments. **Methods:** A total of 55 MDR *M. tuberculosis* isolates and H37Rv were included. MZ and IPZ activity against *M. tuberculosis* isolates were tested using anaerobic culture conditions. The activity of ECO and CLO was measured by the minimal inhibitory concentration (MIC) using a microdilution colorimetric method.

Results: MZ and IPZ showed bacteriostatic activity against *M. tuberculosis* strains. MIC₅₀ and MIC₉₀ to ECO was 4.0 µg/ml, while MIC₅₀ to CLO was 4.0 µg/ml and MIC₉₀ was 8.0 µg/ml respectively.

Conclusion: All azole compounds tested in the study showed inhibitory activity against MDR *M. tuberculosis* clinical isolates.

© 2017 Asociación Argentina de Microbiología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

* Corresponding author.

E-mail address: cataldi.angeladrian@inta.gob.ar (Á.A. Cataldi).

PALABRAS CLAVE

Resistencia
a fármacos;
Imidazoles;
Tuberculosis latente;
Nitroimidazoles

Actividad *in vitro* de azoles contra aislamientos clínicos de *Mycobacterium tuberculosis***Resumen**

Introducción: La tuberculosis (TB) latente ha sido asociada a la persistencia de *Mycobacterium tuberculosis* durmientes en el organismo de las personas infectadas, las cuales constituyen un reservorio del bacilo y una fuente de diseminación de la enfermedad en la comunidad. Urge la necesidad de contar con nuevos fármacos antituberculosos con acción sobre el bacilo en estado latente/durmiente, a fin de evitar reactivaciones endógenas y para ser incluidas en el tratamiento de la TB multirresistente y extensivamente resistente (M/XDR-TB). Se ha reportado que los azoles son activos contra *M. tuberculosis*. Por esta razón, los objetivos del presente estudio fueron determinar la actividad *in vitro* sobre aislamientos clínicos de M/XDR-TB de distintos azoles, incluyendo los imidazoles econazol (ECO) y clotrimazol (CLO) y los 5-nitroimidazoles ipronidazol (IPZ) y metronidazol (MZ), así como analizar su potencial uso contra las formas latente y activa de esta enfermedad.

Métodos: Fueron incluidos 55 aislamientos clínicos de *M. tuberculosis* MDR y la cepa de referencia H37Rv. Se evaluó la actividad del MZ y el IPZ sobre los aislamientos en condiciones de cultivo anaeróbico, mientras que la actividad del ECO y el CLO fue estimada determinando la concentración inhibitoria mínima (CIM) mediante el método colorimétrico de microdilución en placa.

Resultados: El MZ y el IPZ presentaron actividad bacteriostática frente a las cepas de *M. tuberculosis*. La CIM₅₀ y CIM₉₀ del ECO fue de 4 µg/ml, mientras que el CLO presentó una CIM₅₀ de 4 µg/ml y una CIM₉₀ de 8 µg/ml.

Conclusión: Todos los compuestos azólicos evaluados presentaron actividad inhibitoria frente a aislamientos clínicos de *M. tuberculosis*.

© 2017 Asociación Argentina de Microbiología. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Latent tuberculosis (LTB) has been associated with the persistence of dormant *Mycobacterium tuberculosis* in the organism of infected individuals, who are reservoirs of the bacilli and the source for spreading the disease in the community¹⁰.

The World Health Organization (WHO) estimates that one-third of the world population is infected with *M. tuberculosis* and around 10% might develop the disease during their life^{31,32}. In 2013, it was estimated that almost 480 000 new multidrug-resistant tuberculosis (MDR-TB, simultaneously resistant to isoniazid, INH, and rifampicin, RIF) cases occurred worldwide. The extensively drug-resistant TB (XDR-TB) caused by MDR microorganisms with resistance also to an injectable agent (amikacin, kanamycin or capreomycin) and to a fluoroquinolone, has been reported by 100 countries and in accordance with the WHO, around 9.0% of people with MDR-TB have XDR-TB⁹.

From year 2000 to 2012, Argentina reported more than 80 XDR-TB cases with 2.2% of incidence rate among new MDR-TB cases¹⁵.

XDR-TB is considered an almost incurable disease and a limited number of active antibiotics that could be used are available. The contacts of M/XDR cases could also be infected by these resistant mycobacteria, developing and spreading the disease in the community. Therefore, new active anti-TB drugs exerting their metabolic action at

different stages and on latent/dormant bacilli are urgently required to avoid endogenous reactivations and to be part of treatments for M/XDR-TB.

Azole drugs, such as imidazole, econazole (ECO) and clotrimazole (CLO) are widely used antifungal agents, which are also active against some gram positive bacteria. There are many data on their safety, side effects, pharmacokinetics and pharmacodynamics^{4,32}. Furthermore, it has been previously reported that azoles are also active against *in vitro* *M. tuberculosis* and in the mouse model^{2,17,18,24}.

The distribution of Cytochrome P450 (CYP) monooxygenases in fast-growing and slow-growing mycobacteria evidence that these enzymes are highly conserved in the genus *Mycobacterium* unlike other bacteria having no CYP, such as *Escherichia coli*. Azole drugs coordinate to the heme iron of CYPs of the microorganism; therefore, they are potent CYP inhibitors. *M. tuberculosis* contains 20 different CYPs^{11,12,19,23}. There is no doubt about the activity of some azoles against mycobacteria such as PA824, metronidazole (MZ), delamanid, ECO, CLO and many new molecules of chemical synthesis; however, their mechanism of action is not fully elucidated^{20,24}. It has been postulated that the main mechanism of resistance to azoles is the increased drug efflux mediated by the MmpS5-MmpL5 system in *M. tuberculosis*^{11,16,24}.

Antimicrobial drugs that showed no significant activity against *M. tuberculosis* in aerobic culture condition may be active in the dormant state induced by a drop of the oxygen

tension in the culture medium. This suggests the possibility that these drugs may have a place in the chemotherapy of MDR-TB and LTB alone and/or in combination with other drugs²⁸.

Nitroimidazoles are synthetic chemotherapeutic agents that are active against fungi, parasites and anaerobic bacteria, and which have also demonstrated their bactericidal activity against dormant *M. tuberculosis*, since the targets of these drugs are expressed during the latent state^{1,3}. It has been postulated that these drugs exert bactericidal activity by the reduction of its nitro group. Although 5-nitro and 2-nitroimidazoles are available, only the 5-nitro derivative is effective as antibacterial and antiparasitic agent¹⁴. MZ is the main drug of 5-nitroimidazoles and it is believed that it acts as an electron acceptor, inhibiting the released H₂ and ATP production. The active structure of MZ remains unknown; however MZ reduction requires three electrons; therefore it is supposed that there is a free radical or another highly electrophilic molecule acting as electron acceptor. Reduced MZ derivatives act on DNA, producing an extensive break of this molecule as well as, it is believed, a possible inhibition of DNA repair mechanisms⁵. It has also been postulated that MZ is active against *M. tuberculosis* by affecting the synthesis of fatty acids in mycobacteria²². The redox potential of MZ is -420 mV and the lowest potential in aerobic systems is -350 mV, for this reason, MZ is only active under anaerobic conditions.

MZ acts on gram positive, gram negative and anaerobic bacteria. The antiparasitic effect includes amebas, trichomonas and giardias. In *M. tuberculosis*, MZ is considered a prodrug that is activated by mycobacterium enzymes, such as the oxidoreductase formed by Rv2454c and Rv2455c. This enzyme would be expressed around day 25th of incubation under hypoxic culture conditions^{12,13}. Genes codifying for CYP450 are essential for the virulence and persistence of *M. tuberculosis* in the host. It has been previously reported that under hypoxic conditions, MZ has bactericidal activity against non-replicating *M. tuberculosis*²⁵.

Some clinical trials evaluated MZ activity for pulmonary TB demonstrating that it produced early sputum smear and culture negative conversions but it was too neurotoxic and hepatotoxic to be part of a long term anti-TB treatment⁸.

Moreover, delamanid is a MZ derivative recently approved for MDR-TB treatment in combination with other anti-TB drugs (http://ec.europa.eu/health/documents/community-register/2015/20150424131446/anx_131446_es.pdf).

The aims of this study were to determine the *in vitro* activity of azole drugs, imidazole and nitroimidazole against a collection of MDR *M. tuberculosis* clinical isolates to compare the activity of MZ with IPZ and among imidazoles ECO and CLO, and to analyze their potential use in both LTB and the active forms of M/XDR-TB treatments.

In this study we tested MZ and IPZ as a prototype of 5-nitroimidazole compounds.

IPZ (2-isopropyl-1-methyl-5-nitroimidazole) is an antiprotozoal drug similar to MZ that had been used in veterinary medicine, such as in the treatment of histomoniasis, swine dysentery, trichomoniasis and giardiasis in turkeys and dogs^{26,30}. In our knowledge there are no previous reports testing the *in vitro* activity of IPZ on *M. tuberculosis* strains.


Table 1 Number and percentages of *M. tuberculosis* strains considered to be susceptible for each one of the drugs from the REMA and hypoxia experiments

Drug concentration (µg/ml)	Susceptible strains n (%)
<i>Metronidazole</i> ^a	
8.0	36 (65.5)
32.0	52 (94.5)
<i>Ipronidazole</i>	
16.0	25 (100.0)
<i>Econazole</i>	
4.0	55 (100)
<i>Clotrimazole</i>	
16.0	55 (100.0)


^a Three strains showed invalid results.

On the other hand, ECO and CLO were used to test the imidazole activity among our MDR *M. tuberculosis* clinical isolates.

Metronidazole



Ipronidazole



Materials and methods

A retrospective study including a collection of MDR *M. tuberculosis* strains isolated from patients diagnosed in the Reference Laboratory of Tuberculosis Control Program at Dr. Cetrangolo Hospital was conducted.

The Informed consent from each patient was obtained at the moment of the bacteriological TB diagnostic was made. No ethical approval was required for this study since it was a retrospective study that only included *M. tuberculosis* isolates and these experiences did not interfere with treatment decisions or medical behavior. However, approval was obtained from the Ethical Committee of Dr. Cetrangolo Hospital at the moment of the study design.

M. tuberculosis strains and clinical isolates

A total of 55 MDR *M. tuberculosis* strains were included in the study. This collection of MDR-TB strains were kept at -20 °C and at the moment of the study they were unfrozen and sub-cultured in fresh Middlebrook 7H9 broth (M7H9) with OADC enrichment (Becton Dickinson, Buenos Aires, Argentina). *M. tuberculosis* H37Rv ATCC 27294 was used as fully drug-susceptible reference strain (Table 1).

MZ and IPZ activity

In vitro latency model

To obtain anaerobic *M. tuberculosis* cultures (Can), a system adapted from Wayne and Hayes²⁹ was used. Briefly,

vacuum 5 ml Vacutainer tubes (Becton Dickinson, Buenos Aires, Argentina) were filled, using syringe and needle (26 ½), with 3.0 ml M7H9/OADC. Then, the tubes were inoculated with 30 µl 1:100 dilution from a *M. tuberculosis* 1 McFarland suspension that was in the middle of the exponential phase of the growth curve and previously passed three times by syringe and needle (26 ½). These tubes were immediately incubated at 37 °C during 35 days to achieve the hypoxic condition. Hypoxia is indicated by discoloration in the 'control discoloration tube', which was prepared as above mentioned but also adding 1.5 mg/l of methylene blue (MB). MB is decolorized when the culture achieves the hypoxic condition^{27,29}.

In vitro activity of MZ and IPZ in anaerobiosis

MZ (Fluka, VETRANAL™, USA): once cultures of *M. tuberculosis* (H37Rv and MDR clinical isolates) reached hypoxia, 8.0 µg/ml and 32.0 µg/ml of MZ (Fluka, Germany) were added in different tubes to determine MZ activity. A free-drug tube was used as control of mycobacterial growth.

IPZ (Sigma–Aldrich, USA): once *M. tuberculosis* H37Rv achieved the hypoxic condition, 8.0 µg/ml, 16.0 µg/ml, 32.0 µg/ml, 64.0 µg/ml and 128.0 µg/ml were added to determine their activity. MDR *M. tuberculosis* isolates were tested at 16.0 µg/ml and 128.0 µg/ml. A free-drug tube was used as control of mycobacterial growth.

In both cases (MZ/IPZ), the tubes were immediately re-incubated for 15 days at 37 °C.

Determination of time to exit from the hypoxic/dormant state

After 15 incubation days, and in order to remove the MZ/IPZ from the drug-containing tubes, the whole content was transferred to a 15.0 ml sterile empty plastic tube and was centrifuged at 3000 rpm for 10 min in a refrigerated centrifuge. The supernatant was removed and the pellet was washed with 3.0 ml of PBS 1X, vortexing gently and centrifuging again. Afterwards, the pellet was resuspended in 3.0 ml of PBS 1X. Then, 500.0 µl of the washed culture were loaded into a BACTEC MGIT 960/OADC tube (Becton Dickinson, Buenos Aires, Argentina) to evidence the inhibitory effect of the drugs. The EpiCenter Software (Becton Dickinson, Buenos Aires, Argentina) connected to the MGIT system was used to detect the growth units, indicating the exit of dormancy and the restoration of the cellular metabolism in aerobic conditions⁶.

ECO and CLO activity

Determination of the minimal inhibitory concentration (MIC) to ECO and CLO was performed by the previously described resazurin (RES) microtiter assay using 96-well microplates. RES is a redox indicator that changes the color when bacteria consume O₂. Briefly, the outside wells were filled with 200 µl of sterile water and the inside wells with 100 µl of M7H9/OADC medium. Afterwards, 100 µl of ECO or CLO were added, the initial drug concentration being 32.0 µg/ml; then two-fold serial dilutions were performed up to a lower concentration of 1.0 µg/ml of the drug (range: 16.0–8.0–4.0–2.0–1.0–0.5 µg/ml). After adding the drugs




Figure 1 Activity of metronidazole against *M. tuberculosis* strains. UC_CTR, growth units of strains without metronidazole; UC_MZ8, growth units of strains with 8.0 µg/ml of metronidazole; UC_MZ32, growth units of strains with 32.0 µg/ml of metronidazole.

(except in the growth control well, GC), 100 µl of a 1/25 dilution from 1 McFarland standard mycobacterial suspension, containing 10⁶–10⁸ CFU/ml were added in each one of the wells loaded into the plates.

The plates were light-protected and incubated for 5 days at 37 °C. Then, the GC was filled with 30 µl of RES and incubated for one more day. If no color change was evidenced, a second GC well was developed and incubated for 24 h (h) more and so on. When bacterial growth was observed, the remaining wells were filled with RES and re-incubated for 24 h more for the final reading. The MIC was defined as the lowest drug concentration that completely inhibited the microorganism growth, which was evidenced by the absence of color change of the indicator²¹.

Statistics

Variable summary statistics were determined by the MedCalc v. 16.4.3 software (Mariakerke, Belgium). The *t*-test and the multiple line graphs to determine the MZ, IPZ, ECO and CLO activity was used to estimate the significance of the differences between drug activity against *M. tuberculosis*.

Results

Metronidazol and Iprnidazol

MZ was tested as onH37Rv and on a total of 55 MDR *M. tuberculosis* strains. A total of 52 (94.5%) *M. tuberculosis* strains showed valid and interpretable results. Figure 1 shows the global activity of MZ against *M. tuberculosis* strains, with a difference of approximately 2 logarithmic units (2 Ulog, *p* < 0.0001) between the drug-free tube and MZ (8.0 and 32.0 µg/ml)-containing tubes when the mycobacteria reached the exponential growth phase. This difference diminishes throughout the growth curve, and at the mid of the log phase a difference of 1.0 Ulog between the control tube and the MZ (8.0 µg/ml)-containing tube was observed (*p* < 0.0001) while the difference between control tube and MZ (32.0 µg/ml) was 0.4 Ulogs (*p* < 0.0001); furthermore, no




Figure 2 Metronidazole activity against dormant *M. tuberculosis* strains in different phases of the growth curve. (a) UC_To_CTRL/UC_To_Mz8/UC_To_Mz32, growth units to reach the logarithmic phase of the strains without metronidazole/8.0 µg/ml of metronidazole/32.0 µg/ml of metronidazole. (b) UC_T1_2_CTRL/UC_T1_2_Mz8/C_T1_2_Mz32, growth units at the mid of the logarithmic phase of the strains without metronidazole/8.0 µg/ml/32.0 µg/ml of metronidazole. (c) UC_Te_CTRL/UC_Te_Mz8/UC_Te_Mz32, growth units at the stationary phase of the strains without metronidazole/8.0 µg/ml/32.0 µg/ml of metronidazole.

significant difference was observed between both MZ tested concentrations ($p > 0.01$). There was no difference between the Ulog control tube and the MZ-containing tubes (Ulog 0.06 and 0.12 for MZ 8.0 and MZ 32.0 µg/ml respectively, $p > 0.01$) at the moment in which the mycobacterium growths reached the stationary phase.

Figure 2 shows the difference in each phase of the curve for each MZ concentration.

To determine IPZ activity, this drug was first tested on *M. tuberculosis* H37Rv strain. An increased inhibitory effect was observed as long as the drug concentration was also




Figure 3 Effect of different concentrations of ipronidazole (IPZ) on *M. tuberculosis* H37Rv.

increasing. Figure 3 shows the effect at different concentrations of IPZ on dormant *M. tuberculosis* H37Rv.

IPZ activity at 16.0 µg/ml and 128.0 µg/ml was also tested on 25 MDR *M. tuberculosis* isolates. Figure 4 shows the difference in each phase of the curve for each one of the IPZ concentrations tested on the *M. tuberculosis* isolates. As Figure 4 shows, greater activity was observed using IPZ 128.0 µg/ml than 16.0 µg/ml ($p < 0.001$) at the mid of the log phase, while in the stationary phase, no difference was observed between both concentrations tested ($p > 0.01$). Moreover, the 25 MDR *M. tuberculosis* clinical isolates were inhibited by both 5-nitro-imidazole drugs.

Econazol and clotrimazol

ECO and CLO showed inhibitory activity against H37Rv and MDR *M. tuberculosis* clinical isolates. MIC results were as follows: MIC: 0.5 µg/ml (ECO, n: 8, 14.5%; CLO, n: 6, 10.9%), MIC: 2.0 µg/ml (ECO, n: 6, 10.9%; CLO, n: 9, 16.4%), MIC: 4 µg/ml (ECO, n: 41, 74.5%; CLO, n: 15, 27.3%), MIC: 8.0 µg/ml (CLO, n: 17, 30.9%), MIC: 16.0 µg/ml (CLO, n: 8, 14.5%). MIC₅₀₋₉₀ to ECO was 4.0 µg/ml, while MIC₅₀ and MIC₉₀ to CLO was 4.0 µg/ml and 8.0 µg/ml respectively.

Discussion

In this study and under the system used, MZ showed a reversible inhibitory bacteriostatic activity against MDR *M. tuberculosis* strains, although bactericidal activity of MZ was previously reported by other authors²⁸. Long-term (35-day-old) non-replicating *M. tuberculosis* was not sterilized after 15-day-exposure to MZ. The combination of azole drugs plus other anti-TB agents could increase the effect of this kind of drugs¹². At the concentrations of MZ and IPZ tested, a delay was obtained in *M. tuberculosis* growth that was re-established in the stationary phase. This may suggest that the maintenance of constant drug serum levels attained by the dose scheme based on the half-life of the drug, might potentially produce a prolonged inhibitory effect, and could be an effective alternative in MDR-TB treatment or in the chemoprophylaxis of MDR-LTB. According to previous




Figure 4 Iprnidazole activity against dormant MDR *M. tuberculosis* clinical strains in different phases of the growth curve. (a) UC_To_CTRL/UC_To_IPZ16/UC_To_IPZ128, growth units to reach the logarithmic phase of the strains without ipronidazole/16.0 µg/ml of ipronidazole/128.0 µg/ml of ipronidazole. (b) UC.T1.2_CTRL/UC.T1.2_IPZ 16/C.T1.2_IPZ128, growth units at the mid of the logarithmic phase of the strains without ipronidazole/16.0 µg/ml/128.0 µg/ml of ipronidazole. (c) UC.Te_CTRL/UC.Te_IPZ16/UC.Te_IPZ128: growth units at the stationary phase of the strains without ipronidazole/16.0 µg/ml/128.0 µg/ml of ipronidazole.

reports, an average of 8.0 µg/ml (13.0 ± 2.3 µg/ml) is reached in humans using doses of 400 mg of MZ^{7,13}. In this study no inhibitory differences were observed using either 8.0 µg/ml or 32.0 µg/ml of MZ.

Furthermore, the fact that IPZ has also been tested on *M. tuberculosis* provides new preliminary data about the inhibitory effect of another compound of the 5-nitroimidazole family. In this study and under our tested conditions, unlike what was observed with MZ, IPZ inhibited *M. tuberculosis* growth and the greater the concentration of the drug tested, the greater the inhibitory effect.

These observed differences could be related to the action mechanism of each drug and with their pharmacokinetic characteristics. As observed with MZ, the inhibitory effect of IPZ was also bacteriostatic. No previous reports exist about the use of IPZ in humans. It has been used as antiprotozoal agent in animals. IPZ is effective by oral administration in drinking water and feed and also by parenteral administration, *i.e.*, subcutaneous, intramuscular, intravenous, intraperitoneal or intraruminal injection.

Although we used a Wayne adapted hypoxic system based on oxygen deprivation to test nitroimidazole compounds, a bacteriostatic and non-bactericidal effect of these kinds of drugs was observed on *M. tuberculosis* strains. It could suggest that a change in the conditions to achieve the hypoxic culture – like fatty acid deprivation in the liquid medium –, could produce a bactericidal effect of nitroimidazole compounds.

Regarding ECO and CLO, the activity against *M. tuberculosis* isolates was evidenced under aerobic conditions. Furthermore, it was possible to find the MIC value inhibiting most of the mycobacterial amount, suggesting their possible use in combination with other anti-TB drugs for MDR-TB treatment.

Both systems used in this study, allowed us to evaluate the azole activity against *M. tuberculosis* strains. MZ, IPZ, ECO and CLO showed activity against the H37Rv strain and on MDR-TB clinical isolates.

ECO as well as CLO were found to have strong antimycobacterial potential against *M. tuberculosis* under *in vitro* conditions.

This study shows that azole drugs exerted an inhibitory action among a collection of Argentinean MDR clinical isolates. Azole drugs bear significant therapeutic potential against *M. tuberculosis*.

Although the use of MZ for TB treatment has been discarded due to its adverse effects, both 5-nitroimidazoles tested in this study were used as a model of their class of drugs. Results obtained with both drugs suggest that similar kinds of drugs, with fewer side effects than MZ, could be effective in MDR-TB treatment and in the treatment of MDR-LTB caused by contact with an MDR-TB source.

Ethical disclosures

Protection of people and animals. The authors state that no human or animal experiments have been performed for this research.

Confidentiality of the data

The authors state that no patient data appears in this article.

Right to privacy and informed consent. The authors state that no patient data appears in this article.

Funding

No funds were obtained for this work.

Conflict of interest

All authors declare no conflicts of interest.

Acknowledgments

BRI and AAC are fellows from CONICET, Argentina. We thank Marcelo Mazza and Guillermo Alonso for their technical support.

References

- Ahmad Z, Sharma S, Khuller G. The potential of azole antifungals against latent/persistent tuberculosis. *FEMS Microbiol Lett.* 2006;258:200–3.
- Ahmad Z, Sharma S, Khuller G. In vitro and ex vivo antimycobacterial potential of azole drugs against *Mycobacterium tuberculosis* H37Rv. *FEMS Microbiol Lett.* 2005;251:19–22.
- Carroll MW, Jeon D, Mountz JM, Lee JD, Jeong YJ, Zia N, Lee M, Lee J, Via LE, Lee S, Eum SY, Lee SJ, Goldfeder LC, Cai Y, Jin B, Kim Y, Oh T, Chen RY, Dodd LE, Gu W, Dartois V, Park SK, Kim CT, Barry CE 3rd, Cho SN. Efficacy and safety of metronidazole for pulmonary multidrug-resistant tuberculosis. *Antimicrob Agents Chemother.* 2013;57:3903–9.
- Ebden P, Neill P, Farrow P. Sputum levels of fluconazole in humans. *Antimicrob Agents Chemother.* 1989;33:963–4.
- Edwards D. Mechanisms of selective toxicity of metronidazole and other nitroimidazole drugs. *Br J Vener Dis.* 1980;56:285–90.
- Filippini P, Iona E, Piccaro G, Peyron P, Neyrolles O, Fattorini L. Activity of drug combinations against dormant *M. tuberculosis*. *Antimicrob Agents Chemother.* 2010;54:2712–5.
- Gerding DN, Peterse LR, Hughes CE, Bamberger DM. Extravascular antimicrobial distribution in man. In: Lorian V, editor. *Antibiotics in laboratory medicine*. Baltimore: Williams & Wilkins; 1986. p. 938–94.
- Giavini E, Menegola E. Are azole fungicides a teratogenic risk for human conceptus? *Toxicol Lett.* 2010;198:106–11.
- Global Tuberculosis report; 2014. p. 54.
- Gomez JE, McKinney JD. *M. tuberculosis* persistence, latency and drug tolerance. *Tuberculosis.* 2004;1:29–44.
- Ioerger TR, O'Malley T, Liao R, Guinn KM, Hickey MJ, Mohaideen N, Murphy KC, Boshoff HI, Mizrahi V, Rubin EJ, Sassetti CM, Barry CE 3rd, Sherman DR, Parish T, Sacchettini JC. Identification of new drug targets and resistance mechanisms in *Mycobacterium tuberculosis*. *PLoS ONE.* 2013;8:e75245.
- Iona E, Giannoni F, Pardini M, Brunori L, Orefici G, Fattorini L. Metronidazole plus rifampin sterilizes long-term dormant *M. tuberculosis*. *Antimicrob Agents Chemother.* 2007;51:1537–40.
- Lamp K, Freeman N, Klutman N, Lacy M. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. *Clin Pharmacokinet.* 1999;36:353–73.
- Leitsch D, Kolarich D, Wilson IB, Altmann F, Duchene M. Nitroimidazole action in *Entamoeba histolytica*: a central role for thioredoxin reductase. *PLoS Biol.* 2007;5:e211.
- Löffler J, Einsele H, Hebart H, Schumacher U, Hrastnik C, Daum G. Phospholipid and sterol analysis of plasma membranes of azole-resistant *Candida albicans* strains. *FEMS Microbiol Lett.* 2000;185:59–63.
- Lupetti A, Danesi R, Campa M, Del Tacca M, Kelly S. Molecular basis of resistance to azole antifungals. *Trends Mol Med.* 2002;8:76–81.
- McLean KJ, Marshall KR, Richmond A, Hunter IS, Fowler K, Kieser T, Gurcha SS, Besra GS, Munro AW. Azole antifungals are potent inhibitors of cytochrome P450 mono-oxygenases and streptomycetes. *Microbiology.* 2002;148:2937–49.
- McLean KJ, Dunford AJ, Neeli R, Driscoll MD, Munro AW. Structure, function and drug targeting in *Mycobacterium tuberculosis* cytochrome P450 systems. *Arch Biochem Biophys.* 2007;464:228–40.
- McLean KJ, Clift D, Lewis DG, Sabri M, Balding PR, Sutcliffe MJ, Leys D, Munro AW. The preponderance of P450s in the *Mycobacterium tuberculosis* genome. *Trends Microbiol.* 2006;14:220–8.
- Menendez C, Gau S, Lherbet C, Rodriguez F, Inard C, Pasca MR, Baltas M. Synthesis and biological activities of triazole derivatives as inhibitors of InhA and antituberculosis agents. *Eur J Med Chem.* 2011;46:5524–31.
- Morcillo N, Imperiale B, Di Giulio B. Evaluation of MGIT960 and the colorimetric based method for tuberculosis drug susceptibility testing. *Int J Tuberc Lung Dis.* 2010;14:1169–75.
- Mukherjee T, Boshoff H. Nitroimidazoles for the treatment of TB: past, present and future. *Future Med Chem.* 2011;3:1427–54.
- Ouellet H, Johnston JB, Ortiz de Montellano PR. The *Mycobacterium tuberculosis* cytochrome P450 system. *Arch Biochem Biophys.* 2010;493:82–95.
- Parish T, Carroll P. Deletion of cyp125 Confers increased sensitivity to azoles in *Mycobacterium tuberculosis*. *PLOS ONE.* 2015;10:e0133129.
- Piccaro G, Giannoni F, Filippini P, Mustazzolu A, Fattorini L. Activities of drug combinations against *Mycobacterium tuberculosis* grown in aerobic and hypoxic acidic conditions. *Antimicrob Agents Chemother.* 2013;57:1428–33.
- Skirrows S, Bon Durant R, Farley D, Correa J. Efficacy of Iprnidazol against Trichomoniasis in beef bulls. *J Am Vet Med Assoc.* 1985;187:405–7.
- Taneja NK, Tyagi JS. Resazurin reduction assay for screening of anti-tubercular compounds against dormant and actively growing *M. tuberculosis*, *M. bovis* BCG and *M. smegmatis*. *J Antimicrob Chemother.* 2007;60:288–93.
- Wayne L, Sramek H. Metronidazole is bactericidal to dormant cells of *M. tuberculosis*. *Antimicrob Agents Chemother.* 1994;38:2054–8.
- Wayne LG, Hayes LG. An in vitro model for sequential study of shift-down of *Mycobacterium tuberculosis* through two stages of nonreplicating persistence. *Infect Immun.* 1996;64:2062–9.
- Williams OJ, Mc Ewan D, Bertran JD, Griffeder J. Treatment of trichomoniasis. *Aust Vet J.* 1987;64:159–60.
- World Health Organization, Stop TB Partnership 2011, The Global Plan to Stop TB.
- World Health Organization. Global Tuberculosis Report 2013. Argentina. Perfil de Tuberculosis. www.who.int/tb/data.